

Fungal phospholipid metabolism for antifungal drug discovery



^{1,2} Tania C Sorrell

¹ Julianne T Djordjevic

² Sharon CA Chen &

³ Katrina A Jolliffe

¹ Centre for Infectious Diseases and Microbiology and Westmead Millennium Institute, University of Sydney NSW

² Westmead Hospital, Darcy Rd Westmead NSW 2145

³ Department of Chemistry University of Sydney NSW 2066

Tel (02) 9845 6012

Fax (02) 9891 5317

Email tania.sorrell@sydney.edu.au

Invasive fungal infections often respond poorly to antifungal drugs. The fungal invasin phospholipase B (PLB) and/or its biosynthetic pathway are novel targets for drug development. Compounds with structural similarities to phosphatidylcholine, which is a preferred substrate of cryptococcal PLB1, were purchased or synthesised. For many, there was a correlation between antifungal and anti-PLB activity but not all demonstrated selectivity for fungal compared with mammalian phospholipase, and some were toxic to mammalian cells in culture. The most promising, a bis-pyridinium compound, is undergoing toxicity testing in mice. Miltefosine (MI), a stable phospholipid analogue used in the treatment of leishmaniasis also has broad spectrum fungicidal activity, but inhibition of PLB is not its major mode of action. To improve antifungal potency and reduce toxicity of MI, analogues of this alkyl phospholipid have been synthesised and are under investigation.

Invasive fungal infections are a serious and escalating health problem. They are associated with a high morbidity, a mortality varying from 20% to more than 80% and a multibillion dollar economic burden, especially, but not only, in immunocompromised hosts. Current therapies are limited in safety and/or efficacy and resistant fungal pathogens are an emerging problem. Of the antifungal drugs marketed for systemic use, all except the echinocandins (which target the cell wall synthesis enzyme, glucan 3 synthase), act on the fungal membrane protein, ergosterol, or its biosynthetic pathways. Thus new drugs acting on novel targets, and which have activity

against key fungal pathogens and favourable pharmacokinetic and safety profiles, are needed now.

Virulence factors, of which the multifunctional enzyme phospholipase B1 (PLB1) is an example, are potential targets for drug discovery. PLB1 is best characterised in the yeast *Cryptococcus neoformans*¹. It contains three enzyme activities, PLB, lysophospholipase (LPL) and lysophospholipase transacylase (LPTA, Figure 1) and functions as a fungus-specific invasin². The major mammalian cell wall phospholipid, phosphatidylcholine (PC) is a preferred substrate³⁻⁴. PLB is produced and secreted by many pathogenic fungi⁵⁻⁹.

We synthesised and tested three classes of compound with structural similarities to PC as potential inhibitors. Two (alkyl-bis(biguanide) and alkyl-bis(phosphonium)) compounds inhibited both PLB activity and growth of *C. neoformans* and




Figure 1. Structure of a phospholipid, with sites of hydrolysis by different phospholipases shown by arrows. PLB1 has PLB activity but also lysophospholipase activity – a fatty acyl chain is cleaved from a lysophospholipid (structurally similar to the phospholipid shown but with only one fatty acyl chain in the *sn*-1 or *sn*-2 position on the glycerol backbone) and lysophospholipase transacylase (which re-acylates a fatty acyl chain on to the lysophospholipid). Phospholipase A₂ (PLA₂), phospholipase C (PLC) and phospholipase D (PLD) occur widely in mammalian cells.

*C. albicans*¹⁰. This activity was not explained by a non-specific detergent-like action, since there was selectivity of effect between the LPL/LPTA and PLB activities of the enzyme. Analogues of the alkyl-bis(phosphonium) compounds were also active against filamentous fungi including *A. fumigatus*, *A. terreus* and *S. apiospermum*, with MICs similar to those of Amphotericin B¹¹. Although promising, these early prototype compounds were not sufficiently selective for fungal PLB1 compared with mammalian secretory PLA2. We subsequently synthesised a novel structural class of bis-pyridinium compounds, which are completely selective for fungal PLB and not toxic to erythrocytes or nucleated mammalian cells¹². They have broad spectrum antifungal activity and are currently being tested for toxicity in animals prior to efficacy studies in mice.

An additional compound class of interest is represented by the oral anti-leishmanial drug, miltefosine (hexadecylphosphocholine). This is a metabolically stable phospholipid analogue which we have shown has broad spectrum fungicidal activity *in vitro* against yeasts and moulds, including resistant species such as *Candida krusei*, *Candida glabrata*, *Scedosporium prolificans*, *Fusarium* spp. and Zygomycetes¹³. MICs are well below serum levels achieved by oral dosing with miltefosine and there is very preliminary evidence of effect in a mouse model of cryptococcosis and as combination salvage therapy in a child with severe, non-responsive, *S. prolificans* infection. Current investigation is directed to understanding the mode(s) of action of miltefosine in order to develop more potent, less toxic analogues. To date we have established that, although miltefosine inhibits cryptococcal PLB1, it does so only at high concentrations, indicating that this is not its major mode of action.

In conclusion, although the mature enzyme PLB1 is a potential target for antifungal drug development, inhibitor compounds to date appear to exert their antifungal effect through additional pathways. An alternative approach under active investigation is to seek to inhibit cellular synthesis and/or secretion of PLB1¹⁴.

Acknowledgements

Work described in this review was supported by project grants 632634, 402413 and 352354 from the National Health and Medical Research Council of Australia.

References

1. Cox, G.M. *et al.* (2001) Extracellular phospholipase activity is a virulence factor for *Cryptococcus neoformans*. *Mol. Microbiol.* 39, 166–75.
2. Santangelo, R. *et al.* (2004) Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. *Infect. Immun.* 72, 2229–39.
3. Chen, S.C. *et al.* (2000) Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus *Cryptococcus neoformans*. *Biochem. J.* 347, 431–9.
4. Santangelo, R.T. *et al.* (1999) Biochemical and functional characterisation of secreted phospholipase activities from *Cryptococcus neoformans* in their naturally occurring state. *J. Med. Microbiol.* 48, 731–40.
5. Calderone, R.A. & W.A. Fonzi. (2001) Virulence factors of *Candida albicans*. *Trends Microbiol.* 9, 327–35.
6. Ghannoum, M.A. (2000) Potential role of phospholipases in virulence and fungal pathogenesis. *Clin. Microbiol. Rev.* 13, 122–43.
7. Leidich, S.D. *et al.* (1998) Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *J. Biol. Chem.* 273, 26078–86.
8. Mukherjee, P.K. *et al.* (2001) Reintroduction of the PLB1 gene into *Candida albicans* restores virulence *in vivo*. *Microbiology* 147, 2585–97.
9. Shen, D.K. *et al.* (2004) Characterisation and expression of phospholipases B from the opportunistic fungus *Aspergillus fumigatus*. *FEMS Microbiol. Lett.* 239, 87–93.
10. Ganendren, R. *et al.* (2004) *In vitro* antifungal activities of inhibitors of phospholipases from the fungal pathogen *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* 48, 1561–9.
11. Obando, D. *et al.* (2007) Synthesis, antifungal and antimicrobial activity of alkylphospholipids. *Bioorg. Med. Chem.* 15, 5158–65.
12. Obando, D. *et al.* (2009) Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes. *Bioorg. Med. Chem.* 17, 6329–39.
13. Widmer, F. *et al.* (2006) Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. *Antimicrob. Agents Chemother.* 50, 414–21.
14. Sifakas, A.R. *et al.* (2007) Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. *J. Biol. Chem.* 282, 37508–14.

Biographies

Tania Sorrell is Professor of Clinical Infectious Diseases at the University of Sydney and an infectious diseases physician at Westmead Hospital. Her research interests are in the pathogenesis of cryptococcosis, new antifungal drug development and novel diagnostics in mycology.

Julie Djordjevic is a Research Fellow with the University of Sydney and fungal pathogenesis group leader at the Centre for Infectious Diseases and Microbiology, Westmead Millennium Institute. Her research interests include identifying mechanisms of fungal pathogenesis and novel molecular targets for antifungal drug design, and delineating, at the molecular level, the mode of action of novel antifungal compounds.

Sharon Chen is an infectious diseases physician and Medical Microbiologist at Westmead Hospital, Sydney. Her research interests are in clinical and molecular epidemiology of fungal infections including clinical trials, novel diagnostics and antifungal drug resistance.

Kate Jolliffe is a Professor of Chemistry at the University of Sydney. Her research interests include the development of novel antifungal agents, the design and evaluation of molecular receptors for biologically important anions and the synthesis of biologically active cyclic peptides.